Heart scans to predict future heart failure after chemotherapy
Part of Cancer, Heart & circulation, Injuries & trauma clinical trials.
This trial uses detailed heart imaging (a special MRI scan) to see how chemotherapy may have affected your heart and to predict who could develop heart failure later. If you qualify, it may help your care team better monitor your heart health over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You can speak English or Spanish
- You are between 13 and 39 years old
- You were diagnosed with cancer before age 22
- You previously received anthracycline chemotherapy, and your cancer diagnosis was at least 2 years ago
- You can safely have a cardiac MRI scan (no non-MRI-safe metal implants)
- You are not pregnant, and you do not have a more serious congenital (born-with) heart problem
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses heart imaging scans and blood tests to check if a common cancer drug (anthracycline) is affecting your heart during treatment. Early detection might help doctors protect your heart health.
This trial uses a special scoring system (ML Score) to predict if you might develop heart problems while receiving anthracycline chemotherapy or HER2-targeted therapies. It helps doctors decide on the best heart monitoring plan before starting treatment.
This study watches how chemotherapy and HER2-targeted drugs affect your heart during early-stage breast cancer treatment. Researchers use heart scans to catch any changes early and understand how to protect heart health.
This study looks at how chemotherapy and other cancer treatments affect the heart in children. It aims to find heart problems early so they can be treated quickly.
This study looks for people who may be developing heart failure early, using heart imaging and related checks. If you fit the risk pattern, the results may help find heart failure sooner in similar people.
This trial tests whether a personalized, risk-based heart care plan can help prevent heart failure in people who had certain cancer treatments. It focuses on monitoring and guiding treatment, using heart ultrasound results and other health factors.
Hear when a new Cardiotoxicity trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.